Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #713

    Er der nogen der har et klokkeslet for offentliggørelsen af asco-abstr i morgen?

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #714

      evening US, so I expect your summary on thursday morning 😉

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #715

        😉

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JohnW
          wrote on sidst redigeret af
          #716

          Zymeworks: https://finance.yahoo.com/news/zymeworks-enters-first-zymelink-antibody-104500488.html

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Schiff
            wrote on sidst redigeret af
            #717

            Synes ikke der er meget RTOR over den MAIA ansøgning. Jeg ved ikke om jeg forstår den her tegning https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review-pilot-program men kan det passe at Janssen completed sBLA submission den 12. marts? https://johnsonandjohnson.gcs-web.com/static-files/5cec96a8-449f-4608-8890-a83c0b00d0b9 Herfra går der ifølge FDA ca. 4 uger? nu er der så gået 8 uger.

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #718

              Det tror jeg vi er mange der spørger om. Men mon ikke vi er tæt på jf Genmab (JW, Andrew)

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #719

                Winkel fra CC om RTOR og Maia: It's up to the gods at the FDA right now, but I think the process is going well, and there is no reason to be concerned at all. It's an experimental program. It's a pilot program. So the time lines are not fixed, but we expect it very, very shortly.

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #720

                  har der ikke været nævnt 20.5 her i debatten?

                  1 Reply Last reply
                  0
                  • royalR Offline
                    royalR Offline
                    royal
                    wrote on sidst redigeret af
                    #721

                    Jeg smider et par flasker god hvidvin i køleskabet. De overlever ikke til lørdag morgen. (Uanset hvad 😉 )

                    1 Reply Last reply
                    0
                    • royalR Offline
                      royalR Offline
                      royal
                      wrote on sidst redigeret af
                      #722

                      De fleste af os forventede at RTOR var lig med meget hurtig behandlingstid. Vi er nu meget klogere.

                      1 Reply Last reply
                      0
                      • K Offline
                        K Offline
                        KWC
                        wrote on sidst redigeret af
                        #723

                        Capital Increase in Genmab as a Result of Employee Warrant Exercise
                        Company Announcement

                        Copenhagen, Denmark; May 14, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,737 shares as a consequence of the exercise of employee warrants.

                        The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

                        3,000 shares at DKK 40.41,
                        5,000 s

                        1 Reply Last reply
                        0
                        • K Offline
                          K Offline
                          KWC
                          wrote on sidst redigeret af
                          #724

                          Proceeds to the company are approximately DKK 1.61 million. The increase corresponds to approx. 0.02% of the company's share capital.

                          The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2019. The new shares will be listed on Nasdaq Copenhagen after registration with th

                          1 Reply Last reply
                          0
                          • K Offline
                            K Offline
                            KWC
                            wrote on sidst redigeret af
                            #725

                            with the Danish Business Authority. The capital increase is expected to be finalized shortly.

                            1 Reply Last reply
                            0
                            • K Offline
                              K Offline
                              KWC
                              wrote on sidst redigeret af
                              #726

                              3,000 shares at DKK 40.41,
                              5,000 shares at DKK 174.00,
                              188 shares at DKK 225.90,
                              500 shares at DKK 231.50,
                              187 shares at DKK 337.40, and
                              862 shares at DKK 466.20.

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                Plimsoller
                                wrote on sidst redigeret af
                                #727

                                God morgen 🙂

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  polle1
                                  wrote on sidst redigeret af
                                  #728

                                  God morgen og god dag 🙂

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #729

                                    God morgen. 🙂

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JohnW
                                      wrote on sidst redigeret af
                                      #730

                                      God morgen 🙂

                                      1 Reply Last reply
                                      0
                                      • K Offline
                                        K Offline
                                        KWC
                                        wrote on sidst redigeret af
                                        #731

                                        Det har du ret i Pensionist ☺️

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #732

                                          Angående linket til Zymeworks, så bliver det faktisk en konkurrent til Genmab/SGs tisotumab vedotin, men selvfølgelig langt ude i fremtiden:

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger